Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 13;25(1):461.
doi: 10.1186/s12885-025-13804-x.

Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer

Affiliations

Integration of intratumoral and peritumoral CT radiomic features with machine learning algorithms for predicting induction therapy response in locally advanced non-small cell lung cancer

FangHao Cai et al. BMC Cancer. .

Abstract

Objectives: To extract intratumoral, peritumoral, and integrated intratumoral-peritumoral CT radiomic features, develop multi-source radiomic models using various machine learning algorithms to identify the optimal model, and integrate clinical factors to establish a nomogram for predicting the therapeutic response to induction therapy(IT) in locally advanced non-small cell lung cancer.

Methods: This study included 209 patients with locally advanced non-small cell lung cancer (LA-NSCLC) who received IT as the training cohort, and an external validation cohort comprising 50 patients from another center. Radiomic features were extracted from intratumoral, peritumoral, and integrated intratumoral-peritumoral regions by manually delineating the gross tumor volume (GTV) and an additional 3 mm surrounding area. Three machine learning algorithms-Support Vector Machine (SVM), XGBoost, and Gradient Boosting-were employed to construct radiomic models for each region. Model performance was evaluated in the external validation cohort using metrics such as Area Under the Curve (AUC), confusion matrix, accuracy, precision, recall, and F1 score. Finally, a comprehensive nomogram integrating the optimal radiomic model with independent clinical predictors was developed.

Results: Through a comparison of optimal machine learning algorithms, INTRAPERI, INTRA, and PERI achieved the best performance with Gradient Boosting, SVM, and XGBoost, respectively. Compared to the INTRA_SVM and PERI_XGBoost INTRA models, the fusion model that integrates INTRA and peritumoral regions within a 3 mm margin around the tumor (INTRAPERI_GradientBoosting) showed better predictive performance in the training set, with AUCs of 93.7%, 82.5%, and 89.4%, respectively. In the clinical model, the PS score was identified as an independent predictive factor. The nomogram combining clinical factors with the INTRAPERI_GradientBoosting score demonstrated clinical predictive value.

Conclusion: The INTRAPERI_GradientBoosting model, which integrates intra-tumoral and peritumoral features, performs better than the INTRA intra-tumoral and PERI peritumoral radiomics models in predicting the efficacy of IT therapy in LA-NSCLC. Additionally, the nomogram based on INTRAPERI intra-tumoral and peritumoral features combined with independent clinical predictors has clinical predictive value.

Keywords: CT imaging; Induction therapy; Intra-tumoral features; Locally advanced; Machine learning; Nomogram; Non-small cell lung cancer (NSCLC); Peritumoral features; Predictive model; Radiomics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of Sichuan University West China Longquan Hospital (Approval No. IRB-C-F10/AF-KY-2024028) and conducted in accordance with the Declaration of Helsinki. Given that this is a retrospective analysis and all patient data were anonymized, the Ethics Committee waived the requirement for individual informed consent. Similarly, approval for the external validation cohort was obtained from the Ethics Committee of the Cancer Center of the Second Affiliated Hospital of Chongqing Medical University (Approval No. KY2024394). All data processing procedures adhered to relevant ethical standards and privacy protection regulations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Analysis Workflow. The workflow consists of the following steps: Feature Extraction: Radiomic and dosimetric features are extracted from lung tissue regions. Feature Selection and Modeling: Features are extracted and selected from intra-tumoral, 3 mm peritumoral, and fused intra-peritumoral regions using correlation analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and embedded logistic regression with three machine learning classification algorithms. Model Evaluation: Model performance is assessed through discrimination and calibration metrics. Clinical Application Assessment: The clinical applicability is evaluated using a nomogram and decision curve analysis
Fig. 2
Fig. 2
Flowchart of patient enrollment, eligibility, and exclusion criteria
Fig. 3
Fig. 3
Coefficients for feature selection in fused intra-peritumoral, intra-tumoral, and peritumoral regions
Fig. 4
Fig. 4
Nomogram of the comprehensive predictive model combining the 3 mm peritumoral-fused intra-peritumoral feature model with clinical predictive factors
Fig. 5
Fig. 5
Predictive performance of the final model’s radiomic features, clinical parameters, and comprehensive nomogram in the training cohort. decision curve analysis and calibration curves
Fig. 6
Fig. 6
Predictive performance of radiomic features, clinical parameters, and the comprehensive nomogram in the external validation cohort. Includes decision curve analysis and calibration curves

Similar articles

Cited by

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229–263. 10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751. - PubMed
    1. Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L. Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 2023 Mar 28. 10.1097/CM9.0000000000002529. Epub ahead of print. PMID: 37027426. - PMC - PubMed
    1. Bravis V, Kaur A, Walkey HC, Godsland IF, Misra S, Bingley PJ, Williams AJK, Dunger DB, Dayan CM, Peakman M, Oliver NS, Johnston DG. ADDRESS-2 management committee, patient advocate group and investigators. Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open. 2018;8(4):e020904. 10.1136/bmjopen-2017-020904. PMID: 29622578; PMCID: PMC5893930. - PMC - PubMed
    1. Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y. Management of locally advanced non-small cell lung cancer: state of the Art and future directions. Cancer Commun (Lond). 2024;44(1):23–46. Epub 2023 Nov 20. PMID: 37985191; PMCID: PMC10794016. - PMC - PubMed
    1. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D’Amico TA, Dilling TJ, Dowell J, Gettinger S, Gubens MA, Hegde A, Hennon M, Lackner RP, Lanuti M, Leal TA, Lin J, Loo BW Jr, Lovly CM, Martins RG, Massarelli E, Morgensztern D, Ng T, Otterson GA, Patel SP, Riely GJ, Schild SE, Shapiro TA, Singh AP, Stevenson J, Tam A, Yanagawa J, Yang SC, Gregory KM, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. 10.6004/jnccn.2021.0013. PMID: 33668021. - PubMed

MeSH terms